Traitement des tumeurs neuro-endocrines par les peptides radiomarqués

Beierwalters, 1979, Adrenal scanning Schlumberger, 1998, Papillary and follicular thyroid carcinoma, N Engl J Med, 338, 297, 10.1056/NEJM199801293380506 Matthay, 1998, Phase I dose escalation of 131I-mIBG with autologous bone marrow support in refractory neuroblastoma, J Clin Oncol, 16, 229, 10.1200/JCO.1998.16.1.229 Krenning, 1989, Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin, Lancet, 1, 242, 10.1016/S0140-6736(89)91258-0 Reubi, 2000, Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use, Eur J Nucl Med, 3, 273, 10.1007/s002590050034 Virgolini, 2001, New trends in peptide receptors radioligands, Q J Nucl Med, 45, 153 Tenenbaum, 2000, Scintigraphie des récepteurs de la somatostatine (Octreoscan®) : exploration des tumeurs neuro-endocrines (TNE) d’origine digestive, Med Ther, 2, 423 Baudin, 2002, Biology and imaging of neuro-endocrine tumors, Rev Prat, 52, 268 Lebtahi, 1998, Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors, Gastroenterology, 115, 1025, 10.1016/S0016-5085(98)70282-3 Barakat, 2004, Neuroendocrine tumours, Endo Relat Cancer, 11, 1, 10.1677/erc.0.0110001 Mitry, 1999, Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin, Br J Cancer, 81, 1351, 10.1038/sj.bjc.6690325 Krenning, 1994, Radiotherapy with a radiolabeled somatostatin analogue, 111 Indium- DTPA- D Phe1- octreotide, Ann NY Acad Sci, 733, 495, 10.1111/j.1749-6632.1994.tb17300.x Valkema, 2002, Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience, Semin Nucl Med, 2, 110, 10.1053/snuc/2002.31025 Anthony, 2002, Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies, Semin Nucl Med, 2, 123, 10.1053/snuc.2002.31769 Otte, 1999, Yttrium-90 DOTATOC: first clinical results, Eur J Nucl Med, 11, 1439, 10.1007/s002590050476 Waldherr, 2001, The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study, Ann Oncol, 7, 941, 10.1023/A:1011160913619 Waldherr, 2002, Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq (90)Y-DOTATOC, J Nucl Med, 5, 610 Bodei, 2003, Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study, Eur J Nucl Med Mol Imaging, 2, 207, 10.1007/s00259-002-1023-y Jamar, 2003, 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SM487)- A phase 1 escalating study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acide co-infusion, Eur J Nucl Med Mol Imaging, 4, 510, 10.1007/s00259-003-1117-1 Bodei, 2004, Receptor radionuclide therapy with (90)Y-(DOTA)(0)-Tyr(3)-octreotide ([90]Y-DOTATOC) in neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 7, 1038 Kwekkeboom, 2003, Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate, Eur J Nucl Med Mol Imaging, 3, 417, 10.1007/s00259-002-1050-8 Cremonesi, 1999, Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications internal radiotherapy with 90Y-DOTATOC, Eur J Nucl Med, 26, 77, 10.1007/s002590050462 Valkema, 2006, Survival and response after peptide receptor radionuclide therapy with (90Y-DOTA0, Tyr3)octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors, Semin Nucl Med, 36, 147, 10.1053/j.semnuclmed.2006.01.001 Kwekkeboom, 2008, Treatment with the radiolabeled somatostatin analog (177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival, J Clin Oncol, 26, 2124, 10.1200/JCO.2007.15.2553 De Jong, 2002, Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings, Semin Nucl Med., 2, 133, 10.1053/snuc.2002.31027